Biotricity Inc. (“Biotricity”) today announced its financial results for the third quarter of fiscal 2025 year and (unaudited) ended December 31, 2024.  Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, “In the third quarter of fiscal 2025, we continued our mission to innovate and develop transformative healthcare technologies, while demonstrating our strong commitment to automation, operating efficiency and financial discipline. Our primary focus remains on driving revenue and margins and as such, we were pleased to see these metrics trend upwards. This quarter we continued to leverage our data intelligently, pushing the boundaries of what’s possible in healthcare outcomes through cutting-edge research and development. This dedication has allowed us to redefine medical diagnostics and patient care by introducing innovative AI-driven solutions”.

Biotricity Inc. (“Biotricity”) and B-Secur, a leader in biosensing technology, have joined forces to create one of the most advanced, device-neutral platforms for integrated heart monitoring.  By combining B-Secur’s HeartKey^® technology, a suite of FDA-cleared algorithms and analytics, with Biotricity’s medical and consumer diagnostic solutions, the new partnership will empower Integrated Delivery Networks, healthcare providers, health systems, and Independent Diagnostic Testing Facilities with enhanced capabilities for Ambulatory Cardiac Monitoring and ambulatory devices.

Biotricity Inc. (“Biotricity”) today announced that it has completed a series of financings that bolster the Company’s financial health, reduce execution risk, and provide it with the necessary resources to achieve profitability.  As disclosed within the financial filing of its most recent quarter, the Company added $811 thousand dollars of capital in the form of promissory and convertible promissory notes, thereby more than matching $635 thousand of additional term loan proceeds from its term loan lender.

Biotricity Inc. (Biotricity) announces the launch of a new cardiac monitoring pilot program with a top hospital system. With 90% of U.S. adults at risk of developing cardiovascular disease and a projected shortage of up to 124K physicians in the next 12 years, the demand for Biotricity’s innovative cardiac monitoring solutions has never been more urgent.  Integration of Biotricity’s advanced cardiac monitoring solutions into major hospitals will poise the company to play a crucial role in reshaping how cardiovascular health and other chronic diseases are managed.

Biotricity Inc. (Biotricity) today announced the launch of a new cardiac monitoring pilot program with a prominent hospital group encompassing 60 sites spread across multiple states.  Biotricity’s cardiac monitoring solution is the only three-channel connected solution in the world. This unique technology results in superior diagnostics, reduced patient risk, and enhanced workflow efficiency, providing improved clinical outcomes while lowering overall healthcare costs.

Biotricity Inc. (Biotricity) today announces the highly anticipated launch of its direct-to-consumer heart health screening program, HeartSecure. HeartSecure represents a monumental leap forward in cardiac monitoring, providing users with unparalleled convenience, affordability, and peace of mind. By increasing access to heart monitoring and empowering individuals to take control of their cardiac health, Biotricity is helping reshape cardiac care.

Biotricity Inc. (Biotricity) has announced the expansion of its cardiac diagnostics portfolio through strategic partnerships with a leading home-based neurology company and a leading home-based sleep apnea diagnostic company. Individuals suffering from sleep or neurological disorders have elevated risks for cardiac issues. These collaborations position Biotricity and its partners as comprehensive providers of holistic screenings, marking a significant advancement in Biotricity’s mission to offer integrated healthcare solutions that address the complex needs of patients with multiple conditions.